BBB National Programs Newsroom

NAD Recommends Arcadia Consumer Healthcare Discontinue Its “#1 Pharmacist Recommended” Claim

For Immediate Release 
Contact: Abby Hills, Director of Communications, BBB National Programs 

703.247.9330 / press@bbbnp.org 

New York, NY – September 8, 2020 – The National Advertising Division of BBB National Programs found that Arcadia Consumer Healthcare did not provide sufficiently reliable evidence to support its “#1 Pharmacist Recommended” claim and recommended the claim, challenged by Advantice Health, be discontinued. The advertiser agreed to comply with NAD’s recommendation.  

Express Claim 

  • “#1 Pharmacist Recommended” 


Implied Claim 

  • Fungi-Nail antifungal products, which treat athlete’s foot, including the Fungi-Nail Anti-Fungal Pen, Fungi-Nail Anti-Fungal Liquid, and Fungi-Nail Anti-Fungal Ointment, are the #1 Pharmacist Recommended” brand/product for all fungal infections. 


As support for the challenged claims, the advertiser submitted a survey to assess “the awareness and recommendation level of 5 OTC products which treat fungus on the skin around the toenail.” The five products included in the pharmacist-directed survey were Fungi-Nail, FungiCure, ProClearz, Tineacide, and Mycocide. The survey asked “When recommending a brand or product that treats fungus on the skin around the toenail, what brands or products do you recommend? (select all that apply).” The results demonstrated that 73% of the surveyed pharmacists recommend Fungi-Nail. 

Although NAD determined that the survey had an appropriate survey population, was geographically diverse, and asked a question designed to assess what products the pharmacists actually recommend in their practice, the five products included in the survey were not representative of the entire OTC antifungal marketplace. Lamisil, Lotrimin, and Tinactin, the undisputed brand leaders, were not listed as options for the pharmacists to recommend in the survey.  

NAD was not persuaded by the advertiser’s contention that it is a specialty product and, therefore, belonged in a different product category than the leading antifungal brands obviating the need to compare Fungi-Nail to the brand leaders in the survey. Moreover, the survey was conducted on a prior product formulation instead of the current product formulation. Lastly, the survey was further flawed by its failure to ask open-ended questions and impermissibly conflated brand claims and product claims. NAD therefore recommended the advertiser discontinue the “#1 Pharmacist Recommended” claim. 

In its advertiser’s statement, the advertiser stated that it “appreciates NAD’s attention to this matter and agrees to comply.” 

### 

About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org. 

About the National Advertising Division: The National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.     

NAD Recommends Arcadia Consumer Healthcare Discontinue Its “#1 Pharmacist Recommended” Claim

For Immediate Release 
Contact: Abby Hills, Director of Communications, BBB National Programs 

703.247.9330 / press@bbbnp.org 

New York, NY – September 8, 2020 – The National Advertising Division of BBB National Programs found that Arcadia Consumer Healthcare did not provide sufficiently reliable evidence to support its “#1 Pharmacist Recommended” claim and recommended the claim, challenged by Advantice Health, be discontinued. The advertiser agreed to comply with NAD’s recommendation.  

Express Claim 

  • “#1 Pharmacist Recommended” 


Implied Claim 

  • Fungi-Nail antifungal products, which treat athlete’s foot, including the Fungi-Nail Anti-Fungal Pen, Fungi-Nail Anti-Fungal Liquid, and Fungi-Nail Anti-Fungal Ointment, are the #1 Pharmacist Recommended” brand/product for all fungal infections. 


As support for the challenged claims, the advertiser submitted a survey to assess “the awareness and recommendation level of 5 OTC products which treat fungus on the skin around the toenail.” The five products included in the pharmacist-directed survey were Fungi-Nail, FungiCure, ProClearz, Tineacide, and Mycocide. The survey asked “When recommending a brand or product that treats fungus on the skin around the toenail, what brands or products do you recommend? (select all that apply).” The results demonstrated that 73% of the surveyed pharmacists recommend Fungi-Nail. 

Although NAD determined that the survey had an appropriate survey population, was geographically diverse, and asked a question designed to assess what products the pharmacists actually recommend in their practice, the five products included in the survey were not representative of the entire OTC antifungal marketplace. Lamisil, Lotrimin, and Tinactin, the undisputed brand leaders, were not listed as options for the pharmacists to recommend in the survey.  

NAD was not persuaded by the advertiser’s contention that it is a specialty product and, therefore, belonged in a different product category than the leading antifungal brands obviating the need to compare Fungi-Nail to the brand leaders in the survey. Moreover, the survey was conducted on a prior product formulation instead of the current product formulation. Lastly, the survey was further flawed by its failure to ask open-ended questions and impermissibly conflated brand claims and product claims. NAD therefore recommended the advertiser discontinue the “#1 Pharmacist Recommended” claim. 

In its advertiser’s statement, the advertiser stated that it “appreciates NAD’s attention to this matter and agrees to comply.” 

### 

About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org. 

About the National Advertising Division: The National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.     

Blog

Enhancing Brand Safety: Understanding Self-Regulation vs. Independent Industry Self-Regulation

With copious amounts of content proliferating across a growing number of platforms and websites, it is an ongoing challenge for advertisers and platforms to ensure that digital ads are not placed next to harmful content. In this conversation, there is a key distinction few are making — the difference between ‘self-regulation’ and ‘independent, industry-wide self-regulation.’
Read more
Blog

CFBAI and CCAI Published the 2020 Annual Report on Participant Compliance and Program Progress

BBB National Programs has released the CFBAI and CCAI 2020 Annual Report, which includes findings on CFBAI and CCAI participant compliance with their commitment to advertise only foods that meet CFBAI’s strict Uniform Nutrition Criteria or to not engage in advertising primarily directed to children under age 12. The Report indicates excellent compliance by the 19 CFBAI participants and the eight CCAI participants in 2020.
Read more
Blog

What Do You Need to Know about the Florida Lemon Law?

If you have ever purchased or leased a car or SUV that you consider a lemon, you may have questions about the myriad of federal and state laws that govern your vehicle and the remedies available to you. Each state also has their own statute governing vehicles sold and leased in that state for personal use. Today, we look at the lemon law in Florida, one of the fastest-growing states in the U.S.
Read more
Blog

AI Can Be A Force For Good In Recruiting And Hiring New Employees

A challenge for rapid innovation in any industry is the ability for legal and regulatory requirements to keep pace. In the recruiting and hiring process, where AI provides aid to human decision-making and a welcome relief to managing a deluge of data, company leaders are asking themselves: How can we combine important technological innovation with a proactive approach to employment law requirements?
Read more

NAD Recommends Arcadia Consumer Healthcare Discontinue Its “#1 Pharmacist Recommended” Claim

For Immediate Release 
Contact: Abby Hills, Director of Communications, BBB National Programs 

703.247.9330 / press@bbbnp.org 

New York, NY – September 8, 2020 – The National Advertising Division of BBB National Programs found that Arcadia Consumer Healthcare did not provide sufficiently reliable evidence to support its “#1 Pharmacist Recommended” claim and recommended the claim, challenged by Advantice Health, be discontinued. The advertiser agreed to comply with NAD’s recommendation.  

Express Claim 

  • “#1 Pharmacist Recommended” 


Implied Claim 

  • Fungi-Nail antifungal products, which treat athlete’s foot, including the Fungi-Nail Anti-Fungal Pen, Fungi-Nail Anti-Fungal Liquid, and Fungi-Nail Anti-Fungal Ointment, are the #1 Pharmacist Recommended” brand/product for all fungal infections. 


As support for the challenged claims, the advertiser submitted a survey to assess “the awareness and recommendation level of 5 OTC products which treat fungus on the skin around the toenail.” The five products included in the pharmacist-directed survey were Fungi-Nail, FungiCure, ProClearz, Tineacide, and Mycocide. The survey asked “When recommending a brand or product that treats fungus on the skin around the toenail, what brands or products do you recommend? (select all that apply).” The results demonstrated that 73% of the surveyed pharmacists recommend Fungi-Nail. 

Although NAD determined that the survey had an appropriate survey population, was geographically diverse, and asked a question designed to assess what products the pharmacists actually recommend in their practice, the five products included in the survey were not representative of the entire OTC antifungal marketplace. Lamisil, Lotrimin, and Tinactin, the undisputed brand leaders, were not listed as options for the pharmacists to recommend in the survey.  

NAD was not persuaded by the advertiser’s contention that it is a specialty product and, therefore, belonged in a different product category than the leading antifungal brands obviating the need to compare Fungi-Nail to the brand leaders in the survey. Moreover, the survey was conducted on a prior product formulation instead of the current product formulation. Lastly, the survey was further flawed by its failure to ask open-ended questions and impermissibly conflated brand claims and product claims. NAD therefore recommended the advertiser discontinue the “#1 Pharmacist Recommended” claim. 

In its advertiser’s statement, the advertiser stated that it “appreciates NAD’s attention to this matter and agrees to comply.” 

### 

About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org. 

About the National Advertising Division: The National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.     

 

 

Media Inquiry